Consumer genetic testing company 23andMe announced on Wednesday that GlaxoSmithKline purchased a $300 million stake in the company, allowing the pharmaceutical giant to use 23andMe’s trove of genetic data to develop new drugs — and raising new privacy concerns for consumers.
23andMe is partnering with big pharma company GlaxoSmithKline. Here’s what that means for consumer rights and genetic privacy.
Read more
Comments are closed.